Targeting IL-12β (IL12p40), which constitutes a crossroad between TH1-associated IL-12 and TH17-associated IL-23, is successfully implemented as treatment for psoriasis and is undergoing clinical trials for several other immune-mediated inflammatory diseases (77). The gene discussed is IL12B; the disease is psoriasis.